January 6, 2021

Dr. Ghassan Abou-Alfa

Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. Professor
Abou-Alfa specializes in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, and fibrolamellar carcinoma.

Professor Abou-Alfa is the immediate previous Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force and a member of the NCI AIDS Malignancy Consortium Steering Committee. Professor Abou-alfa is a member of the International Affairs Committee of the American Society of Clinical Oncology (ASCO), and is the President-Elect for the International Society of Gastrointestinal Oncology (ISGIO). Professor Abou-Alfa majored in biology, earned his medical degree, and now serves as a trustee on the Board of Trustees of his alma mater the
American University in Beirut. Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, and received his MBA
from Columbia University.

Professor Abou-Alfa’s research focuses on incorporating small biological molecules into standard cancer therapies. In recent years, his group at MSK led the initial efforts evaluating sorafenib in HCC. Sorafenib was ultimately approved by the FDA for that indication in 2007.

Professor Abou-Alfa more recently his group at MSK led the efforts evaluating cabozantinib which was approved by the FDA for HCC indication in January 2019. He now focuses on determining the right CAR-T antigens for HCC and analyzing world wide data to help analyze the genetic profile of patients with HCC and help determine the appropriate targeted therapy that will be most valuable. Professor Abou-Alfa has also championed key work in determining novel
targeted therapies for cholangiocarcinoma and gallbladder cancer, targeting IDH-1, FGR-2, and
Her-2. He later led the efforts of pemigatinib, which was approved by the FDA in May 2020, for patients with cholangiocarcinoma and FGFR2 alterations.

Professor Abou-Alfa strongly advocates for greater awareness of cancer’s global impact; and continues to lead several international educational and research efforts with different institutions